

Press release



Medicon Valley Scandinavia, February 5, 2007

Vivolution receives 7 million Euros in new financing to take the Vivostat System to the US market

The second generation Vivostat product named PRF (platelet rich fibrin) addresses the multibillion dollar market for the treatment of chronic wounds

Vivolution today signed a 7 million Euro financing deal. Lead investors are French based venture fund SEVENTURE and Danish privately owned venture fund VECATA. The existing shareholders Vækstfonden, Dansk Innovationsinvestering and Dansk Kapitalanlæg all participate in the new round.

Tom Bjerg Lauritzen CEO of Vivolution A/S is very enthusiastic about the new and aggressive financing. “We are about to launch our second generation product for the treatment of chronic wounds. With the new investment we will be able to build our organisation to support this launch and also begin the approval process for PRF on the US market.”

“Vivolution is our third life science investment in Denmark and confirms our desire to invest outside France especially in the Medicon Valley”, says Isabelle de Cremoux, general partner in Seventure. ” Vivolution has a well established business in the surgical sealant market with sales of its products already in more than 15 countries and has shown strong growth with limited resources. We want to see faster growth and address the wound care market with the very promising PRF product. With this investment backed by our experienced life science team, Vivolution is well positioned to be successful”, adds Mrs. Cremoux.

“Being the world’s only system for on-site preparation of patient derived surgical sealant and platelet rich fibrin, the Vivostat[®] System is performing a remarkable break-through in growing markets. The combined market potential of the sealant market and the active therapy wound care market is well in excess of 1 billion USD and with the Vivostat[®] System we have proven that so-called next generation products are here and ready to be used.” said Tom Bjerg Lauritzen, CEO, Vivolution.

Press release



About VIVOLUTION

Vivolution is a privately owned company based in the Medicon Valley of Scandinavia. Our product the Vivostat® System utilize the individual patient's blood to derive either a surgical sealant to prevent and stop bleedings or a gel with a high concentration of growth factors to stimulate the healing of chronic wounds. By using the patient's own blood there is no risk of allergic reactions or transfer of viral diseases. This is an increasingly important factor as more and new viruses, such as Asian bird flu etc. develop. The no-risk aspect of the Vivostat® System will be a major pull factor in new, major markets such as Japan. Our Products are sold via distributors throughout Europe and Asia mainly to cardiac, thoracic and hepatic surgeons. More than 98% of our sale is export.

About SEVENTURE

Being one of the leading venture capital firms in Europe, SEVENTURE manages 400 million Euros and invests since 1997 in innovative businesses with high growth potential in Information Technology and Life Sciences all over Europe.

SEVENTURE is a subsidiary of Natexis Private Equity, the asset management company of Natexis-Banque Populaire, which manages €2.5 billion in private equity investments.

In Life sciences, our 3 favoured sectors are biotech & pharmaceuticals, medical device and industrial biotech & chemical, but we also consider investments in diagnostics, drug delivery systems, environment, bio-energy, skin care, nutraceuticals, wellness and services

About Vecata

VECATA A/S is owned by the Bagger-Sørensen family, who also owns Gumlink and Fertin Pharma located in Vejle. The family's company Dandy A/S was sold in 2002 to Cadbury-Schweppes. VECATA A/S investment area comprises venture backed companies and existing companies with attractive growth potential.

For interview please contact:

CEO Tom Bjerg Lauritzen, tel. +45 45 81 19 62, E-Mail: tbl@vivolution.com

For product information please visit: www.vivolution.com